Pharmaceuticals

Research

Jump to: Review

20 pages, 3108 KiB

Open AccessArticle

2-Amino-3-Chlorobenzoic Acid from Streptomyces coelicolor: A Cancer Antagonist Targeting PI3K/AKT Markers via miRNA Modulation

by Ashraf Khalifa, Joseph D. Balthazar, Pandurangan Subash-Babu, Mohamed Y. Zaky, Zeinab A. El-Moaty and Hairul Islam M. Ibrahim

Pharmaceuticals 2025, 18(5), 620; https://doi.org/10.3390/ph18050620 - 24 Apr 2025

Viewed by 329

Abstract

Background/Objectives: Actinomycetes, particularly species within the Streptomyces genus, are renowned for their ability to produce a wide array of bioactive molecules with therapeutic potential. This study aimed to comprehensively investigate the antimicrobial and anticancer properties of Streptomyces coelicolor ERI-15, with a particular focus [...] Read more.

Background/Objectives: Actinomycetes, particularly species within the Streptomyces genus, are renowned for their ability to produce a wide array of bioactive molecules with therapeutic potential. This study aimed to comprehensively investigate the antimicrobial and anticancer properties of Streptomyces coelicolor ERI-15, with a particular focus on a purified compound, 2-amino-3-chlorobenzoic acid (2A3CB), and its efficacy against microbial pathogens and breast cancer cell lines. Methods: Antimicrobial compounds were produced through fermentation techniques and isolated via column chromatography. Bioassay-guided fractionation was conducted against Staphylococcus aureus (ATCC 25923), methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (ATCC 25922), and Bacillus subtilis (ATCC 441). Major fractions were further purified using preparative thin-layer chromatography (TLC). The structures of active compounds were elucidated using spectral analyses including IR, mass spectrometry, and ¹H/¹³C NMR. The compound 2A3CB (m/z 171) was tested against MDA-MB-231 and 3T3 cell lines. Cytotoxicity was assessed by the MTT assay, and apoptotic mechanisms were explored via cell proliferation assays, dual fluorescent staining, migration and invasion assays, and analysis of apoptotic markers at mRNA and protein levels. Results: 2A3CB exhibited strong cytotoxic effects on MDA-MB-231 cells, with IC₅₀ values of 26 µM, 5 µM, and 7.2 µM at 24, 48, and 72 h, respectively. It significantly inhibited cell proliferation and migration, and induced apoptosis via caspase-mediated pathways. Expression levels of PTEN, PCNA, BAX, and STAT3 were downregulated, suggesting inhibition of metastasis through the suppression of invasion and migration. Conclusions: The results demonstrate that 2A3CB, derived from S. coelicolor ERI-15, possesses potent antimicrobial and anticancer properties. Its ability to inhibit growth and induce apoptosis in MDA-MB-231 breast cancer cells highlights its potential as a natural therapeutic candidate for targeted cancer treatment, particularly in breast cancer progression. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

18 pages, 4796 KiB

Open AccessArticle

Exploring the Chemopreventive Potential of Artemisia annua Methanolic Extract in Colorectal Cancer Induced by Azoxymethane in Mice

by Faris Alrumaihi

Pharmaceuticals 2025, 18(1), 34; https://doi.org/10.3390/ph18010034 - 31 Dec 2024

Cited by 1 | Viewed by 1266

Abstract

Background/Objectives: Colorectal cancer (CRC) remains a major global health burden, necessitating innovative preventive approaches. Artemisia annua (A. annua), known for its extensive pharmacological properties, has shown potential in cancer therapy. This study investigates the chemopreventive efficacy of methanolic extract of A. [...] Read more.

Background/Objectives: Colorectal cancer (CRC) remains a major global health burden, necessitating innovative preventive approaches. Artemisia annua (A. annua), known for its extensive pharmacological properties, has shown potential in cancer therapy. This study investigates the chemopreventive efficacy of methanolic extract of A. annua (MEA) in an azoxymethane (AOM)-induced murine model of CRC, with a focus on its antioxidant, biomarker modulation, and pro-apoptotic activities. Methods: MEA was obtained via cold solvent extraction, yielding 39%, and demonstrated potent in vitro cytotoxicity against HCT116 and RKO colon cancer cell lines, with IC50 values of 20 µg/mL and 15 µg/mL, respectively. Swiss albino mice were treated with MEA beginning two weeks before AOM induction, with treatment continuing for 21 weeks. Survival was monitored for 40 weeks. Key outcomes included serum biomarker levels (ADA, GGT, CD73, LDH), antioxidant enzyme activities (SOD, CAT, GPx1, MDA), reactive oxygen species (ROS) modulation, apoptosis induction, and histopathological evaluation. Results: MEA significantly improved survival rates, reduced AOM-induced weight loss, and modulated cancer biomarkers, with marked reductions in ADA, GGT, CD73, and LDH levels. Antioxidant defenses were restored, as evidenced by increased SOD, CAT, and GPx1 activities and decreased MDA levels. ROS levels were significantly reduced, and apoptosis in colonic cells was effectively induced. Histopathological analysis revealed substantial mitigation of CRC-associated morphological abnormalities. Conclusions: MEA exhibits robust chemopreventive properties, demonstrating its potential to reduce oxidative stress, modulate key biomarkers, and induce apoptosis in CRC. These findings position MEA as a promising natural candidate for CRC prevention and therapy, warranting further exploration for clinical application. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Graphical abstract

12 pages, 1333 KiB

Open AccessArticle

Randomized Clinical Evaluation of the Healing Activity of Green Propolis Ointment in Individuals with Lower Limb Ulcers Resulting from Leprosy: Preliminary Results of a Pilot Study

by Cristiano da Rosa, Larissa Kaori Maquedano, Ian Lucas Bueno, Fernando Augusto Lima Marson and Giovanna Barbarini Longato

Pharmaceuticals 2024, 17(12), 1622; https://doi.org/10.3390/ph17121622 - 3 Dec 2024

Viewed by 973

Abstract

Background/Objectives: Treating chronic wounds incurs substantial costs for Brazil’s Unified Health System. Natural compounds, particularly propolis, are increasingly explored as low-cost alternatives due to their healing properties. Brazilian green propolis, distinct in its chemical composition, has garnered scientific interest. This study aimed to [...] Read more.

Background/Objectives: Treating chronic wounds incurs substantial costs for Brazil’s Unified Health System. Natural compounds, particularly propolis, are increasingly explored as low-cost alternatives due to their healing properties. Brazilian green propolis, distinct in its chemical composition, has garnered scientific interest. This study aimed to assess the healing effects of green propolis ointment on lower-limb ulcers from leprosy. Methods: A blinded, randomized clinical trial included 18 wounds in two groups: propolis ointment (G1) and control (G2), with evaluations conducted weekly for 61 days. Wound progress was monitored using morphometry and the Pressure Ulcer Scale for Healing (PUSH). Results: No participants exhibited sensitivity to the propolis. G1 showed significant initial healing: average wound area reduction (%) for G1 vs. G2 included 56.38 vs. 6.13–p < 0.001 (week 1); 79.51 vs. 24.16–p = 0.022 (week 4); and 84.33 vs. 39.73–p = 0.051 (week 7). In G1, the PUSH scores decreased from the beginning, whereas in G2, reductions were observed after three weeks. By week 5, 71.4% of G1 wounds scored below eight points, versus 33.3% in G2. G1 wounds exhibited a reduced area and exudate, as well as revitalized granulation tissue without adverse effects. Conclusions: The findings suggest that green propolis ointment is safe, supports tissue repair and may offer cost-effective treatment benefits. Standard wound dressings are selected to support all healing stages, with an emphasis on antimicrobial action, hemostasis to reduce exudate, and pain-reducing and non-irritant properties. Green propolis ointment meets these criteria, offering a cost-effective treatment that accelerates lesion reduction and encouraging leprosy patients to follow the therapeutic regimen. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Graphical abstract

14 pages, 2643 KiB

Open AccessArticle

Probiotic and Rice-Derived Compound Combination Mitigates Colitis Severity

by Ashraf Khalifa, Mayyadah Abdullah Alkuwayti, Basem M. Abdallah, Enas M. Ali and Hairul Islam M. Ibrahim

Pharmaceuticals 2024, 17(11), 1463; https://doi.org/10.3390/ph17111463 - 31 Oct 2024

Viewed by 904

Abstract

Background: This study investigated the ability of Enterococcus lactis (E. lactis) and Hasawi rice protein lysate (HPL) to suppress colitis induced by dextran sulfate sodium (DSS) in miceColitis is characterized by inflammation of the colon, and exploring potential therapeutic agents could [...] Read more.

Background: This study investigated the ability of Enterococcus lactis (E. lactis) and Hasawi rice protein lysate (HPL) to suppress colitis induced by dextran sulfate sodium (DSS) in miceColitis is characterized by inflammation of the colon, and exploring potential therapeutic agents could lead to improved management strategies. Methods: Male mice were subjected to DSS treatment to induce colitis, followed by supplementation with E. lactis and/or HPL. The study assessed various parameters, including disease activity index (DAI) scores, gut permeability measured using FITC-dextran, and superoxide dismutase (SOD) activity in excised colon tissues from both treated and untreated control groups. Results: E. lactis supplementation significantly alleviated DSS-induced colitis, as evidenced by improved DAI scores and enhanced gut permeability. Notably, E. lactis combined with HPL (0.1 mg/10⁸) exhibited superior tolerance to a 0.5% pancreatin solution compared to E. lactis alone. Both E. lactis and the combination treatment significantly increased SOD activity (5.6 ± 0.23 SOD U/mg protein for E. lactis and 6.7 ± 0.23 SOD U/mg protein for the combination) relative to the Azoxymethane (AOM)/DSS group, suggesting a reduction in oxidative stress. Additionally, pro-inflammatory markers were significantly reduced in the group receiving both E. lactis and HPL compared to the E. lactis-only group. Levels of proteins associated with cell death, such as PCNA, PTEN, VEGF, COX-2, and STAT-3, were significantly decreased by 14.8% to 80% following E. lactis supplementation, with the combination treatment showing the most pronounced effects. Conclusions: These findings suggest E. lactis supplementation may be beneficial for colitis, with HPL potential to enhance its effectiveness. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

21 pages, 971 KiB

Open AccessArticle

Perceived Changes in Anxiety Symptom Burden During Treatment with Bryophyllum pinnatum: A Prospective, Single-Arm Study

by Tiffany Huber, Daniel Krüerke, Timotheus Haeck, Markus Weber, Matthias Kröz, Markus Schlemmer and Ana Paula Simões-Wüst

Pharmaceuticals 2024, 17(11), 1423; https://doi.org/10.3390/ph17111423 - 24 Oct 2024

Cited by 2 | Viewed by 1850

Abstract

Background/Objectives: Bryophyllum spp. preparations are widely used in Anthroposophic Medicine, most often for mental and behavioral disorders, including anxiety. Studies in animals revealed various anxiolytic and neurosedative effects for Bryophyllum pinnatum. We set out to investigate the effectiveness of Bryophyllum 50% chewable [...] Read more.

Background/Objectives: Bryophyllum spp. preparations are widely used in Anthroposophic Medicine, most often for mental and behavioral disorders, including anxiety. Studies in animals revealed various anxiolytic and neurosedative effects for Bryophyllum pinnatum. We set out to investigate the effectiveness of Bryophyllum 50% chewable tablets, a product registered without indication by means of notification in Switzerland, in the treatment of anxiety symptoms in psychiatric and psychosomatic patients. Methods: A total of 99 patients with anxiety symptoms were recruited from the waiting list for an inpatient stay at the hospital “Klinik Arlesheim”, Department of Psychiatry and Psychosomatics; of these, 54 completed the study and returned fully completed questionnaires. Patients were treated with Bryophyllum 50% chewable tablets (350 mg tablets, made from leaf press juice, 3 × 2 per day; Weleda AG Arlesheim, Switzerland) and filled out questionnaires at baseline and after two and three weeks of tablet intake. The primary endpoint of the study was the change in anxiety symptoms measured with the Beck Anxiety Inventory (BAI). Results: A clinically relevant decrease in BAI score from baseline (27.4 ± 12.0) to after two (22.4 ± 12.1; p < 0.001) and three (20.6 ± 12.9; p < 0.001) weeks of treatment was observed. Additional improvements were observed in the secondary endpoints (including in depression, sleep quality, and stress); tolerability and compliance were very good. Conclusions: The results suggest that Bryophyllum 50% chewable tablets have beneficial effects on anxiety-related symptoms. Since the study design does not allow us to conclude causality between treatment and observed improvements, a randomized clinical trial is urgently needed. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

13 pages, 879 KiB

Open AccessArticle

Exploring the Correlation between the PASI and DLQI Scores in Psoriasis Treatment with Topical Ointments Containing Rosa × damascena Mill. Extract

by Diana Ioana Gavra, Dóra Kósa, Ágota Pető, Liza Józsa, Zoltán Ujhelyi, Pálma Fehér, Annamária Pallag, Timea Claudia Ghitea, Simona Frățilă, Tünde Jurca and Ildikó Bácskay

Pharmaceuticals 2024, 17(8), 1092; https://doi.org/10.3390/ph17081092 - 20 Aug 2024

Cited by 1 | Viewed by 1303

Abstract

Psoriasis is a chronic autoimmune skin condition characterized by red, circumscribed, scaly, and erythematous plaques that can cover large skin areas. While conventional treatments such as topical corticosteroids and systemic medications are commonly prescribed, the interest in natural remedies for psoriasis has grown [...] Read more.

Psoriasis is a chronic autoimmune skin condition characterized by red, circumscribed, scaly, and erythematous plaques that can cover large skin areas. While conventional treatments such as topical corticosteroids and systemic medications are commonly prescribed, the interest in natural remedies for psoriasis has grown due to concerns about potential side effects and the desire for alternative treatment options. Rosa × damascena Mill. is rich in bioactive compounds that possess anti-inflammatory, antioxidant, and antimicrobial properties; these properties make Rosa × damascena Mill. a promising candidate for the management of skin disorders such as psoriasis. In our previous studies, we successfully formulated and tested different topical preparations containing Rosa × damascena Mill. In this study, we investigated the correlation between the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores in psoriasis treatment using the abovementioned creams containing Rosa × damascena Mill. extract. Several tests were performed to study the correlation between the PASI and DLQI scores in psoriasis patients. Consequently, we were able to observe an improvement in terms of the area, induration, desquamation, and erythema; such an improvement implicitly produces an improvement in patients’ quality of life. The PASI and DLQI scores showed significant progress between visits. These results confirm Rosa × damascena Mill. to be a promising candidate for the topical treatment of psoriatic lesions. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

11 pages, 947 KiB

Open AccessArticle

Effects of a Dietary Supplement Composed of Baicalin, Bromelain and Escin for Venous Chronic Insufficiency Treatment: Insights from a Retrospective Observational Study

by Selene Francesca Anna Drago, Michelangelo Rottura, Antonino Molonia, Viviana Maria Gianguzzo, Giovanni Pallio, Natasha Irrera, Luana Orlando, Marianna Gigliotti De Fazio, Marilena Isgrò, Natalia Zirilli, Vincenzo Arcoraci and Egidio Imbalzano

Pharmaceuticals 2024, 17(6), 779; https://doi.org/10.3390/ph17060779 - 14 Jun 2024

Cited by 1 | Viewed by 1888

Abstract

Chronic venous insufficiency (CVI) represents a risk factor for cardiovascular events. The first-line treatment includes the use of compression stockings and lifestyle changes. Natural products, such as flavonoids, could be used to improve the effects of compression therapy due to their anti-inflammatory and [...] Read more.

Chronic venous insufficiency (CVI) represents a risk factor for cardiovascular events. The first-line treatment includes the use of compression stockings and lifestyle changes. Natural products, such as flavonoids, could be used to improve the effects of compression therapy due to their anti-inflammatory and anti-oxidant properties. This study aims to evaluate the effects of a dietary supplement containing baicalin, bromeline and escin in CVI patients. A retrospective cohort study was performed by using the medical records of CVI affected outpatients. Patients treated with the dietary supplement were defined as “users”. A modified Venous Clinical Severity Score (VCSS) was calculated, including pain, inflammation, vessels induration and skin pigmentation. All clinical variables were evaluated at baseline (T0), after 30 (T1) and 90(T2) days in “users” and “non-users”. Out of 62 patients, 30 (48.4%) were “users”. No difference was observed between groups at baseline. A lower VCSS value was recorded in “users” than that observed in “non-users” at T2 (7.0 (4.0–9.0) vs. 9.0 (5.0–10.0); p = 0.025). Vessels’ induration and pain significantly reduced in 53.3% and 43.3% of “users” and in 18.8% and 9.4% of “non-users”. Only “users” (33.3%) showed a reduction of the inflammatory signs as well as a decrease in malleolar circumference, from 29.0 (26.5–30.0) to 27.5 (26.0–28.5) (p < 000.1). A reduction of C-reactive Protein levels was found in “users” compared to “non-users” at T2 (1.0 (0.9–1.2) vs. 1.3 (1.0–1.5); p = 0.006). These findings suggest that implementation of a dietary supplement could improve the clinical outcomes of CVI patients. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Graphical abstract

10 pages, 753 KiB

Open AccessArticle

Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants—A Double-Blind Randomised Controlled Study

by David Briskey, Rachael Skinner, Chelsie Smith and Amanda Rao

Pharmaceuticals 2024, 17(2), 145; https://doi.org/10.3390/ph17020145 - 23 Jan 2024

Cited by 5 | Viewed by 7264

Abstract

Migraines are a common neurological disorder that generally affects young to middle-aged adults and females more than males. Various treatment options are available; however, these can cause undesirable side effects. Therefore, alternative treatments with minimal side effects are still being investigated. Palmitoylethanolamide (PEA) [...] Read more.

Migraines are a common neurological disorder that generally affects young to middle-aged adults and females more than males. Various treatment options are available; however, these can cause undesirable side effects. Therefore, alternative treatments with minimal side effects are still being investigated. Palmitoylethanolamide (PEA) is a signalling lipid known to have anti-inflammatory and analgesic properties. Previous prophylactic research has reported PEA supplementation to decrease pain associated with migraines. Upon commencement of migraine symptoms, participants were supplemented with either 600 mg of PEA (Levagen+) or a placebo (maltodextrin). Once a dose was taken, participants recorded a visual analogue scale (VAS) for pain every 30 min for 4 h or until the migraine resolved. If the migraine had not resolved 2 h post-dose, participants were instructed to take a second dose. Levagen+ supplementation resolved more headaches after 2- and 8 h, had a lower VAS for pain score at 1.5 and 4 h, and reduced rescue medication use significantly more than a placebo. No adverse events were reported in either group. Overall, PEA was safe and effective in reducing migraine pain, duration, and medication use in an otherwise healthy adult population. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

Review

Jump to: Research

32 pages, 1631 KiB

Open AccessReview

Dilemmas in Elderly Diabetes and Clinical Practice Involving Traditional Chinese Medicine

by Chongxiang Xue, Ying Chen, Yuntian Bi, Xiaofei Yang, Keyu Chen, Cheng Tang, Xiaolin Tong, Linhua Zhao and Han Wang

Pharmaceuticals 2024, 17(7), 953; https://doi.org/10.3390/ph17070953 - 16 Jul 2024

Cited by 1 | Viewed by 2106

Abstract

Diabetes is a widespread chronic disease that occurs mainly in the elderly population. Due to the difference in pathophysiology between elderly and young patients, the current clinical practice to treat elderly patients with anti-diabetes medications still faces some challenges and dilemmas, such as [...] Read more.

Diabetes is a widespread chronic disease that occurs mainly in the elderly population. Due to the difference in pathophysiology between elderly and young patients, the current clinical practice to treat elderly patients with anti-diabetes medications still faces some challenges and dilemmas, such as the urgent need for early diagnosis and prevention, and an imbalance between restricted dietary intake and the risk of undernutrition. Traditional Chinese medicine (TCM) offers various treatment regimens that are actively utilized in the field of diabetes management. Through multiple targets and multiple pathways, TCM formulas, medicinal herbs, and active natural products enhance the efficacy of diabetes prevention and diabetes control measures, simplify complex medication management, and improve common symptoms and common diabetic complications in elderly people. Historically, natural products have played a key role in material composition analysis of TCM and mechanism interpretation to enable drug discovery. However, there have been few conclusions on this topic. This review summarizes the development of TCM for the prevention and management of diabetes in elderly people, existing evidence-based clinical practices, and prospects for future development. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

22 pages, 1799 KiB

Open AccessReview

Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus

by Julianah Ore Abiola, Ayoola Abidemi Oluyemi, Olajumoke Tolulope Idowu, Oluwatoyin Mary Oyinloye, Chukwudi Sunday Ubah, Olutunmise Victoria Owolabi, Oluwatobi T. Somade, Sunday Amos Onikanni, Basiru Olaitan Ajiboye, Foluso Oluwagbemiga Osunsanmi, Oyekanmi Nash, Olaposi Idowu Omotuyi and Babatunji Emmanuel Oyinloye

Pharmaceuticals 2024, 17(6), 736; https://doi.org/10.3390/ph17060736 - 5 Jun 2024

Cited by 6 | Viewed by 6057

Abstract

Currently, there is no known cure for diabetes. Different pharmaceutical therapies have been approved for the management of type 2 diabetes mellitus (T2DM), some are in clinical trials and they have been classified according to their route or mechanism of action. Insulin types, [...] Read more.

Currently, there is no known cure for diabetes. Different pharmaceutical therapies have been approved for the management of type 2 diabetes mellitus (T2DM), some are in clinical trials and they have been classified according to their route or mechanism of action. Insulin types, sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose cotransporter type 2 inhibitors, and incretin-dependent therapies (glucagon-like peptide-1 receptor agonists: GLP-1R, and dipeptidyl peptidase 4 inhibitors: DPP-4). Although some of the currently available drugs are effective in the management of T2DM, the side effects resulting from prolonged use of these drugs remain a serious challenge. GLP-1R agonists are currently the preferred medications to include when oral metformin alone is insufficient to manage T2DM. Medicinal plants now play prominent roles in the management of various diseases globally because they are readily available and affordable as well as having limited and transient side effects. Recently, studies have reported the ability of phytochemicals to activate glucagon-like peptide-1 receptor (GLP-1R), acting as an agonist just like the GLP-1R agonist with beneficial effects in the management of T2DM. Consequently, we propose that careful exploration of phytochemicals for the development of novel therapeutic candidates as GLP-1R agonists will be a welcome breakthrough in the management of T2DM and the co-morbidities associated with T2DM. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

43 pages, 1100 KiB

Open AccessEditor’s ChoiceReview

Hive Products: Composition, Pharmacological Properties, and Therapeutic Applications

by Roberto Bava, Fabio Castagna, Carmine Lupia, Giusi Poerio, Giovanna Liguori, Renato Lombardi, Maria Diana Naturale, Rosa Maria Bulotta, Vito Biondi, Annamaria Passantino, Domenico Britti, Giancarlo Statti and Ernesto Palma

Pharmaceuticals 2024, 17(5), 646; https://doi.org/10.3390/ph17050646 - 16 May 2024

Cited by 10 | Viewed by 5364

Abstract

Beekeeping provides products with nutraceutical and pharmaceutical characteristics. These products are characterized by abundance of bioactive compounds. For different reasons, honey, royal jelly, propolis, venom, and pollen are beneficial to humans and animals and could be used as therapeutics. The pharmacological action of [...] Read more.

Beekeeping provides products with nutraceutical and pharmaceutical characteristics. These products are characterized by abundance of bioactive compounds. For different reasons, honey, royal jelly, propolis, venom, and pollen are beneficial to humans and animals and could be used as therapeutics. The pharmacological action of these products is related to many of their constituents. The main bioactive components of honey include oligosaccharides, methylglyoxal, royal jelly proteins (MRJPs), and phenolics compounds. Royal jelly contains jelleins, royalisin peptides, MRJPs, and derivatives of hydroxy-decenoic acid, particularly 10-hydroxy-2-decenoic acid (10-HDA), which possess antibacterial, anti-inflammatory, immunomodulatory, neuromodulatory, metabolic syndrome-preventing, and anti-aging properties. Propolis has a plethora of activities that are referable to compounds such as caffeic acid phenethyl ester. Peptides found in bee venom include phospholipase A2, apamin, and melittin. In addition to being vitamin-rich, bee pollen also includes unsaturated fatty acids, sterols, and phenolics compounds that express antiatherosclerotic, antidiabetic, and anti-inflammatory properties. Therefore, the constituents of hive products are particular and different. All of these constituents have been investigated for their properties in numerous research studies. This review aims to provide a thorough screening of the bioactive chemicals found in honeybee products and their beneficial biological effects. The manuscript may provide impetus to the branch of unconventional medicine that goes by the name of apitherapy. Full article

(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Therapeutic Effects of Natural Products and Their Clinical Research

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (11 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI